
Background. Repeated exposure to adversity is universal to the human experience and may impact mental health negatively. However, competing hypotheses predict that repeated adversity leads to either sensitisation or habituation. Methods. Using a 22-year Australian population-based panel study, we examined changes in mental health following repeated exposure to seven common adverse life events in adulthood. Mixed-effects regression models estimated the relationship between repeated exposure to adverse life events of the same type and its impact on the Mental Health Inventory-5 score. Results. All seven adverse life events were associated with significant negative mental health impacts at each occurrence. Patterns of mental health response to repeated exposure varied by event type in the primary analysis. Sensitisation was observed for major worsening in finances and victimisation by property crime. Habituation was observed for separation/divorce and serious personal injury/illness. For physical violence, serious family injury/illness, and firing/ redundancy, we found no clear associations. Sensitisation and habituation effects appeared to 'plateau' after the second adverse event rather than accumulating with exposure. Strength and direction of associations were robust to adjustments for pre-event mental health and a Mundlak correction. Conclusions. In a population-based sample over two decades we found event-specific sensitisation and habituation in response to repeated adverse life events. Both effects appeared to 'plateau' after the second event. Our findings provide no consistent support for a single universal model of stress-response, indicating that how individuals respond psychologically to adversity is more nuanced and may depend on contextual factors such as individual meaning, resilience, or resources.
Abstract Background Approximately half of individuals with major depressive disorder (MDD) do not respond to cognitive behavioral therapy (CBT). Cognitive distancing is a reappraisal tactic central to CBT, and neural responses during reappraisal have been linked to psychotherapy outcome. We examined whether pretreatment effective connectivity during cognitive distancing was associated with CBT response in adults with MDD. Methods Seventy-seven outpatients with MDD (31 women) completed fMRI during a distancing task before 25 CBT sessions as part of the SPeED trial, which included a pre-CBT phase of exercise or waiting list. Dynamic causal modeling estimated effective connectivity within a 10-region network. Group differences were assessed with parametric empirical Bayes, and predictive utility was evaluated with leave-one-out cross-validation. Results Responders ( n = 39) showed greater relative modulation along a dorsomedial-to-ventrolateral prefrontal-to-superior frontal/pre-supplementary motor area cascade during distancing, whereas nonresponders exhibited greater relative modulation of amygdala-to-ventrolateral prefrontal cortex connectivity. Nonresponders showed decreased dorsolateral prefrontal self-inhibition during negative picture processing, consistent with heightened local excitability. Distancing-related effects exceeded 99% posterior probability and predicted treatment response in cross-validation ( r = .21–.31, p < .05). Conclusions Effective connectivity during distancing robustly differentiated responders from nonresponders, with nonresponders showing weaker intra-prefrontal control and stronger amygdala-to-prefrontal influence. These neural patterns contribute to insight into CBT nonresponse and suggest a mechanism associated with lowered symptom improvement through cognitive interventions. However, incremental predictive value beyond baseline clinical measures was modest. If replicated prospectively, such measures may contribute to multimodal prediction models and adjunctive treatment strategies. Clinical trials registration name Neurobiological correlates and mechanisms of the augmentation of psychotherapy with endurance exercise in mild to moderate depression – SPeED, http://apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00008869 , DRKS00008869.
Abstract Background Although type 2 diabetes mellitus (T2DM) has twice the self-harm risk of the general population, the role of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) is unclear; this study aimed to assess whether SGLT-2i use is linked to lower self-harm risk in T2DM. Methods Through the Shenzhen Public Health Data Platform, we constructed two cohorts (SGLT-2i vs. dipeptidyl peptidase-4 inhibitors [DPP-4i], and SGLT-2i vs. glucagon-like peptide-1 receptor agonists [GLP-1RA]) via a target trial emulation framework. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using overlapping weighting Cox regression models. Results The SGLT-2i versus DPP-4i cohort included 85,789 SGLT-2i users and 53,810 DPP-4i users. After a median follow-up of 1.85 years (interquartile range: 0.91–2.70), 567 (0.66%) cases of self-harm occurred in the SGLT-2i group and 567 (1.05%) in the DPP-4i group. After overlapping weighting, SGLT-2i was associated with a lower risk of self-harm compared with DPP-4i (HR: 0.86, 95% CI: 0.76–0.98), and this result was consistent across various sensitivity analyses. In the SGLT-2i ( n = 130,330) versus GLP-1RA ( n = 5,126) cohort, a lower risk of self-harm (HR: 0.76, 95% CI: 0.59–0.99) was associated with SGLT-2i compared with GLP-1RA. However, in some sensitivity analyses, no statistically significant difference was observed between SGLT-2i and GLP-1RA users. Conclusions SGLT-2i use is associated with a lower risk of self-harm compared with DPP-4i and GLP-1RA. These findings provide supportive evidence for the safety of SGLT-2i and highlight their potential role in the mental health management of T2DM patients.
Abstract Background Neuromelanin-sensitive MRI (NM-MRI) provides a noninvasive measure of signal within monoaminergic nuclei, including the substantia nigra/ventral tegmental area (SN–VTA) and locus coeruleus (LC). These signals are thought to reflect long-term monoaminergic-related processes. Although presynaptic dopamine dysfunction is implicated in schizophrenia, the contribution of monoaminergic-related NM-MRI signal alterations to treatment-response heterogeneity, including clozapine nonresponse, remains unclear. Methods We conducted a cross-sectional NM-MRI study, including patients with ultra-resistant schizophrenia (URS; n = 16), clozapine-responsive treatment-resistant schizophrenia (non-URS; n = 16), first-line antipsychotic responders (FLR; n = 20), and healthy controls (HCs; n = 26). NM-MRI contrast ratios (CR) were quantified in the SN–VTA and LC. Group differences were assessed using covariate-adjusted models, and voxel-wise analyses were performed to localize SN–VTA effects. Results SN–VTA CR was higher in both URS ( d = 1.01) and FLR ( d = 0.94) than in HCs, with voxel-wise analyses localizing these effects mainly to dorsal SN–VTA regions. In contrast, LC CR was higher in URS than in FLR ( d = 0.99), whereas URS did not differ significantly from HCs. NM-MRI signals were not associated with symptom severity or cognitive measures. Conclusions These findings support the view that schizophrenia treatment-response subgroups may differ in long-term monoaminergic-related (NM-MRI) signal patterns. Elevated NM-MRI signal within dopaminergic nuclei may characterize both antipsychotic-responsive and clozapine nonresponsive schizophrenia, whereas additional noradrenergic involvement may contribute to severe treatment resistance. NM-MRI may help characterize biologically meaningful heterogeneity within treatment-resistant schizophrenia.
Abstract Background Evidence indicates the potential efficacy of trauma-focused therapies for post-traumatic stress disorder (PTSD) in psychosis. This is the first randomized controlled trial to evaluate the superiority of Prolonged Exposure (PE), Eye Movement Desensitization and Reprocessing therapy (EMDR), and Cognitive Restructuring (CR) plus treatment as usual, compared to a waiting-list (WL) plus treatment as usual control group. Methods We conducted a multicenter, assessor-masked, randomized controlled trial in patients with a lifetime schizophrenia spectrum psychotic disorder and PTSD. Participants ( N = 162) were randomized (1:1:1:1) to PE, EMDR, CR, or WL and followed up until 6 months post-randomization. Therapy conditions had a maximum of 16 twice-weekly sessions. Primary outcome was researcher-rated PTSD symptom severity (Clinician-Administered PTSD Scale for DSM-5; CAPS-5). Results PE, EMDR, and CR significantly reduced PTSD severity compared to WL over time from baseline to 6-month follow-up. At 6-months, adjusted differences and between-group effect sizes on the CAPS-5 were −9.76 (95% CI −16.13,−3.38; p = 0.0029) with d = −0.90 (95% CI −1.36,−0.44) for PE, −11.74 (95% CI −18.04,−5.44; p = 0.0003) with d = −1.04 (95% CI −1.50,−0.58) for EMDR, and −12.72 (95% CI −18.89,−6.55; p = 0.0001) with d = −1.00 (95% CI −1.46,−0.54) for CR. Significant therapy effects were also found for secondary PTSD (-related) outcomes, but not for psychosis. Conclusions In comparison to WL, PE, EMDR, and CR were effective in reducing PTSD symptoms in individuals with PTSD and psychosis, with large effects. Replication in larger samples is needed, although these results support expanding access to trauma therapies in this underserved population.